EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made effective as of September 23, 2013, by and between Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason Amello, an individual resident in the Commonwealth of Massachusetts (“Executive”).
CAMBRIDGE SCIENCE CENTER AND 245 FIRST STREET CAMBRIDGE, MASSACHUSETTS OFFICE LEASE AGREEMENT BETWEEN MA-RIVERVIEW/245 FIRST STREET, L.L.C. a Delaware limited liability company (“LANDLORD”) AND AKEBIA THERAPEUTICS, INC., a Delaware corporation (“TENANT”)Office Lease Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
This Exhibit is attached to and made a part of the Office Lease Agreement (the “Lease”) by and between MA-RIVERVIEW/245 FIRST STREET, L.L.C., a Delaware limited liability company (“Landlord”), and AKEBIA THERAPEUTICS, INC., a Delaware corporation (“Tenant”), for space in the Office Building located at 245 First Street, Cambridge, Massachusetts 02142. Capitalized terms used but not defined herein shall have the meanings given in the Lease.
Amendment No. 1 to EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) to EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made as of April 6, 2011, by and between Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), and Joseph Gardner, an individual resident in the State of Ohio (“Executive”).
CONSULTING AGREEMENTConsulting Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Ohio
THIS CONSULTING AGREEMENT (this “Agreement”) is made as of September 15, 2013, by and between Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), and Joseph H. Gardner (“Gardner”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Ohio
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of May 2, 2007, by and between Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), and Joseph H. Gardner, an individual resident in the State of Ohio (“Executive”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Ohio
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of April 6, 2011 (the “Effective Date”) by and between Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), and Dr. Robert Shalwitz, an individual resident in the State of Ohio (“Executive”).
SEPARATION AGREEMENTSeparation Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Ohio
This Separation Agreement (“Agreement”) is made as of September 15, 2013 (but in no case before the Termination Date), by and between Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), and Joseph H. Gardner (“Employee”) under the following circumstances:
SEPARATION AGREEMENTSeparation Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Separation Agreement (“Agreement”) is made as of February 7, 2014, by and between Akebia Therapeutics, Inc. (the “Company”) and William Daly (“Employee”) under the following circumstances (Employee and the Company collectively referred to as the “Parties” or individually referred to as a “Party”). This Agreement shall become effective on the eighth day after its execution by Employee (the “Effective Date”), provided that Employee has not revoked this Agreement as set forth in Paragraph 4 of the below Acknowledgment.
AMENDMENT NUMBER TWO TO THE SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENTRight of First Refusal and Co-Sale Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT NUMBER TWO TO THE SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (the “Amendment”) is made and effective as of May 10, 2013, by and among AKEBIA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and those Investors executing and delivering a counterpart signature page hereto. Capitalized terms not defined herein have the meanings given them in that certain Second Amended and Restated Right of First Refusal and Co-Sale Agreement, dated as of April 6, 2011, as amended by Amendment No. 1 thereto, by and among the Company, the Investors and the Major Holders (as amended, the “Agreement”).
FORGIVENESS AND RELEASE AGREEMENTForgiveness and Release Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
THIS FORGIVENESS AND RELEASE AGREEMENT (this “Agreement”) is made this 30th day of January, 2014, by and between Akebia Therapeutics, Inc., a Delaware corporation (the “Corporation”) and Robert Shalwitz (“Shalwitz,” each of the Corporation and Shalwitz a “Party,” and Corporation and Shalwitz together the “Parties”).
AMENDED AND RESTATED ADMINISTRATIVE SERVICES AGREEMENTAdministrative Services Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Delaware
ContractConsulting Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This letter agreement (“Agreement”) will confirm the agreement between you and Akebia Therapeutics, Inc. (the “Company”) concerning your engagement to provide certain consulting services.
AMENDMENT NO. 1 TO THE THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO THE THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Amendment”) is made and effective as of May 31, 2013, by and among Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), and the “Investors” as defined in that certain Third Amended and Restated Investors’ Rights Agreement, dated as of May 10, 2013, by and among the Company and the Investors a party thereto (the “Agreement”). Capitalized terms not defined herein have the meanings given them in the Agreement.
SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENTRight of First Refusal and Co-Sale Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT is made as of the 6th day of April, 2011 by and among AKEBIA THERAPEUTICS, INC., a Delaware corporation (the “Company”), the Investors listed on Schedule A and the Major Holders listed on Schedule B.
THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • February 14th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 10th day of May, 2013 by and among AKEBIA THERAPEUTICS, INC., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and collectively, the “Investors”), and any Additional Investor that becomes a party to this Agreement in accordance with Section 6.9 hereof.
